- Conditions
- Prostatic Neoplasms
- Interventions
- MLN2704 (DM1 conjugated monoclonal antibody MLN591)
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 4
- States / cities
- New York, New York • Durham, North Carolina • Cleveland, Ohio
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2353–2376
of 3,920
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Prostate Cancer
- Interventions
- flexible AIR coil, endorectal coi
- Device
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer
- Interventions
- carbon-11 acetate PET scan
- Procedure
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- Male only
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2015
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head & Neck Cancer
- Interventions
- 124I-NM404
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Preventive Screening, Prostate Cancer, Osteoporosis, Colorectal Cancer
- Interventions
- Quantitative Information Sheet, Qualitative Information Sheet, Narrative Information Sheet, Framed Information Sheet
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 775 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Prostate Cancer, Health Behavior
- Interventions
- Prostate Cancer Genius App, US Prevention Taskforce App
- Behavioral
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 55 Years to 69 Years · Male only
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Ovarian Cancer, Breast Cancer, Prostate Cancer
- Interventions
- LY2606368
- Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer (Adenocarcinoma)
- Interventions
- Abiraterone, Enzalutamide, Apalutamide, Darolutamide (BAY 1841788), Docetaxel, ADT
- Drug
- Lead sponsor
- Canadian Cancer Trials Group
- Network
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 830 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 374
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 272 more
- Conditions
- Lung Cancer, Tobacco Use Disorder, Breast Cancer, Colorectal Cancer, Prostate Cancer
- Interventions
- Nicotine Replacement Patch
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Prostate Cancer, Sexual Dysfunction and Infertility
- Interventions
- finasteride, flutamide, quality-of-life assessment
- Drug · Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- Male only
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2010
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 26 more
- Conditions
- Prostate Cancer
- Interventions
- 99mTc MIP 1404, 99mTc MIP 1405
- Radiation
- Lead sponsor
- Molecular Insight Pharmaceuticals, Inc.
- Industry
- Eligibility
- 21 Years and older · Male only
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Neoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer, Colorectal Cancer
- Interventions
- XL092, Atezolizumab, Avelumab
- Drug
- Lead sponsor
- Exelixis
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 325 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 40
- States / cities
- Duarte, California • La Jolla, California • Los Angeles, California + 33 more
- Conditions
- ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, BRIP1 Gene Mutation, CDK12 Gene Mutation, CHEK1 Gene Mutation, CHEK2 Gene Mutation, DNA Damage Response Gene Mutation, DNA Repair Gene Mutation, FANCA Gene Mutation, FANCD2 Gene Mutation, FANCL Gene Mutation, GEN1 Gene Mutation, NBN Gene Mutation, Prostate Carcinoma, RAD51 Gene Mutation, RAD51C Gene Mutation
- Interventions
- Niraparib, Niraparib Tosylate Monohydrate, Radical Prostatectomy
- Drug · Procedure
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Prostate Cancer Metastatic Disease
- Interventions
- Hypocaloric anti-inflammatory diet
- Behavioral
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 2
- States / cities
- Los Angeles, California
- Conditions
- Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
- Interventions
- NUV-868, Olaparib, Enzalutamide
- Drug
- Lead sponsor
- Nuvation Bio Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 17
- States / cities
- Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 13 more
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel plus doxercalciferol, Docetaxel plus placebo
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Locally Recurrent Prostate Cancer
- Interventions
- PRX302
- Drug
- Lead sponsor
- Sophiris Bio Corp
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 2
- States / cities
- San Antonio, Texas • Temple, Texas
- Conditions
- Prostate Cancer
- Interventions
- recombinant interferon alfa-2b, docetaxel, estramustine phosphate sodium, isotretinoin, polyacrylamide gel electrophoresis, protein expression analysis, immunohistochemistry staining method
- Biological · Drug · Genetic + 1 more
- Lead sponsor
- University of Medicine and Dentistry of New Jersey
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Osteoporosis, Prostate Cancer
- Interventions
- management of therapy complications
- Procedure
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- Male only
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2007
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Prostate Cancer
- Interventions
- Standard of care ADT + (HMB + arginine + glutamine), Standard of care ADT
- Drug · Other
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 60 Years and older · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Prostate Adenocarcinoma, Lower Urinary Tract Symptoms
- Interventions
- Bicalutamide implant
- Combination Product
- Lead sponsor
- Alessa Therapeutics Inc.
- Industry
- Eligibility
- 35 Years and older · Male only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Prostate Cancer
- Interventions
- 225Ac-J591, Pembrolizumab, Androgen receptor inhibitor, 68Ga-PSMA-11
- Drug · Diagnostic Test
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2029
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Brooklyn, New York • New York, New York
- Conditions
- Prostate Neoplasms
- Interventions
- PS-341 (bortezomib)
- Drug
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Prostate Cancer (Adenocarcinoma), mCRPC (Metastatic Castration-resistant Prostate Cancer)
- Interventions
- Talazoparib with enzalutamide, Talazoparib
- Drug
- Lead sponsor
- Prostate Cancer Clinical Trials Consortium
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 126 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 8
- States / cities
- Duarte, California • La Jolla, California • Boston, Massachusetts + 5 more